Phaseline

Companies › Alzamend Neuro

Alzamend Neuro: clinical trials, targets and expected readouts

2 active drug programs in 10 registered trials: 4 Phase 1, 3 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Oncology, Other, Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lithium Carbonate (AL001)
Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor
IMPA1, GSK3A, GSK3BPhase 1Bipolar I Disorder; Healthy; Bipolar II Disorder; Depression, Bipolar …Dec 2026
ALZN002
Autologous dendritic cells pulsed with amyloid-beta E22W mutant peptide
–Phase 1Alzheimer DiseaseMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06861842Lithium Carbonate (AL001)Phase 4HealthyOtherApr 2025
NCT07540338Lithium Carbonate (AL001)Phase 1Bipolar I DisorderPsychiatryDec 2026
NCT06789783Lithium Carbonate (AL001)Phase 2Cornelia De Lange SyndromeOtherDec 2026
NCT06339034Lithium Carbonate (AL001)Phase 1Parkinson DiseaseNeurologyAug 2027
NCT06776848Lithium Carbonate (AL001)Phase 1Proven Pathogenic or Probably Pathogenic TBR1 VariantOtherSep 2027
NCT06184581Lithium Carbonate (AL001)Phase 4Bipolar II DisorderPsychiatryDec 2027
NCT05834296ALZN002Phase 1Alzheimer DiseaseNeurologyMar 2028
NCT05973786Lithium Carbonate (AL001)Phase 3Bipolar DepressionPsychiatryJun 2028
NCT05913947Lithium Carbonate (AL001)Phase 4Depression, BipolarPsychiatrySep 2028
NCT06051240Lithium Carbonate (AL001)Phase 2Cognitive ImpairmentOncologyAug 2030

From the company's SEC filings

Cash of $8m on 2026-07-31; operating cash outflow about $5m a year; runway about 20 months at that burn, to Mar 2028; 1 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

IMPA1 (1) GSK3A (1) GSK3B (1)

Companies with the same targets

AMO Pharma Actuate Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.